BR112012023015A2 - imunoensaios para lenalidomida e talidomida - Google Patents

imunoensaios para lenalidomida e talidomida

Info

Publication number
BR112012023015A2
BR112012023015A2 BR112012023015A BR112012023015A BR112012023015A2 BR 112012023015 A2 BR112012023015 A2 BR 112012023015A2 BR 112012023015 A BR112012023015 A BR 112012023015A BR 112012023015 A BR112012023015 A BR 112012023015A BR 112012023015 A2 BR112012023015 A2 BR 112012023015A2
Authority
BR
Brazil
Prior art keywords
lenalidomide
thalidomide
immunoassays
immunogens
quantitation
Prior art date
Application number
BR112012023015A
Other languages
English (en)
Inventor
Volkov Alexander
Sard Howard
Blake Courtney Jodi
J Salamone Salvatore
Hedge Vishnumurthy
Original Assignee
Saladax Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saladax Biomedical Inc filed Critical Saladax Biomedical Inc
Publication of BR112012023015A2 publication Critical patent/BR112012023015A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

imunoensaios para lenalidomida e talidomida. a presente invenção refere-se a novos conjugados e imunógenos derivados de lenalidomida e anticorpos gerados por esses imunógenos são úteis em imunoensaios para a quantificação de monitoração de talidomida e lenalidomida e fluidos biológicos.
BR112012023015A 2010-03-12 2011-02-23 imunoensaios para lenalidomida e talidomida BR112012023015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/722,829 US8114621B2 (en) 2010-03-12 2010-03-12 Lenalidomide and thalidomide immunoassays
PCT/US2011/025883 WO2011112358A1 (en) 2010-03-12 2011-02-23 Lenalidomide and thalidomide immunoassays

Publications (1)

Publication Number Publication Date
BR112012023015A2 true BR112012023015A2 (pt) 2017-06-06

Family

ID=44560359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023015A BR112012023015A2 (pt) 2010-03-12 2011-02-23 imunoensaios para lenalidomida e talidomida

Country Status (9)

Country Link
US (5) US8114621B2 (pt)
EP (1) EP2544540B1 (pt)
JP (1) JP2013522594A (pt)
CN (2) CN104730254A (pt)
AU (1) AU2011224719B2 (pt)
BR (1) BR112012023015A2 (pt)
CA (1) CA2790508A1 (pt)
HK (1) HK1175071A1 (pt)
WO (1) WO2011112358A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029548B2 (en) * 2011-05-06 2015-05-12 Catabasis Pharmaceuticals, Inc. Fatty acid lenalidomide derivatives and their uses
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
WO2014121033A1 (en) 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
WO2015200837A1 (en) 2014-06-27 2015-12-30 Fl Therapeutics Llc Abiraterone derivatives and non-covalent complexes with albumin
US10201617B2 (en) * 2014-10-24 2019-02-12 Zhuhai Beihai Biotech Co., Ltd. 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020006812A (es) 2017-12-26 2020-11-06 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
US20220356185A1 (en) * 2018-07-06 2022-11-10 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
EP4009979A4 (en) * 2019-08-09 2023-08-23 The Regents of the University of California ANTIBODY-BASED CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES AND THEIR APPLICATIONS
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
TW202304525A (zh) * 2021-04-14 2023-02-01 南韓商樂高化學生物科學股份有限公司 蛋白質降解劑偶聯物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996344A (en) 1972-05-15 1976-12-07 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies and use
US4016146A (en) 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20060024768A1 (en) * 2004-07-29 2006-02-02 Saladax Biomedical, Inc. Taxol immunoassay
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
US7569358B2 (en) * 2005-03-30 2009-08-04 Saladax Biomedical Inc. Doxorubicin immunoassay
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
CN101501071A (zh) * 2006-05-31 2009-08-05 Lpath公司 对溶血磷脂酸具有反应性的免疫衍生部分
US8268592B2 (en) * 2008-07-17 2012-09-18 Kyowa Hakko Kirin Co., Ltd Anti-system ASC amino acid transporter 2 (ASCT2) antibody

Also Published As

Publication number Publication date
CN102917587A (zh) 2013-02-06
AU2011224719B2 (en) 2014-10-23
US20140024807A1 (en) 2014-01-23
EP2544540A1 (en) 2013-01-16
US20120064549A1 (en) 2012-03-15
EP2544540A4 (en) 2013-08-07
US8440796B2 (en) 2013-05-14
AU2011224719A1 (en) 2012-09-06
WO2011112358A1 (en) 2011-09-15
US20130211052A1 (en) 2013-08-15
HK1175071A1 (en) 2013-06-28
CA2790508A1 (en) 2011-09-15
US20110223611A1 (en) 2011-09-15
EP2544540B1 (en) 2015-04-08
US8114621B2 (en) 2012-02-14
CN102917587B (zh) 2015-04-29
US20120071632A1 (en) 2012-03-22
JP2013522594A (ja) 2013-06-13
US8293492B2 (en) 2012-10-23
CN104730254A (zh) 2015-06-24

Similar Documents

Publication Publication Date Title
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
FR23C1023I2 (fr) Anticorps anti-il-36r
CY2019040I1 (el) Aνti-il-23 αντισωματα
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
BRPI1011005A2 (pt) anticorpos anti-epcam
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
CR20110238A (es) Anticuerpos muc1*
BR112012030311A2 (pt) anticorpo
UY34206A (es) Anticuerpo monoclonal de interleucina-31
CO6811812A2 (es) Anticuerpo anti-b7-h3
BR112013017009A2 (pt) anticorpos anti-cd38
DK2825559T3 (da) Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
DK2651436T3 (da) Mycobakterie antigen sammensætning.
CR20130266A (es) PROTEÍNAS DE UNIÓN AL TNF-a
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
CR20140127A (es) Anticuerpo anti-abtcr
BR112013015122A2 (pt) anticorpos anti-notch1
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
MX337203B (es) Novedosas moleculas inhbidoras de jnk.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]